8-K filing — Profound Medical Corp. (PROF)
Filed: 2026-10-22 AccNo: 0001171843-26-006781 Size: 229 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Profound Medical Appoints Richard Fabian As President, Effective Immediately, Succeeding Mathieu Burtnyk
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen
Profound Medical shares are trading higher after the company issued Q3 sales guidance above estimates.
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
Profound Medical Reports Q2 2026 Results: Full Earnings Call Transcript
Profound Medical (TSX:PRN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Profound Medical Sees Q3 Sales $9.800M-$10.000M vs $6.934M Est
Profound Medical (NASDAQ:PROF) sees Q3 sales of $9.800 million-$10.000 million vs $6.934 million analyst estimate.